Literature DB >> 19914722

The neural-glial purinergic receptor ensemble in chronic pain states.

Michael F Jarvis1.   

Abstract

Chronic pain is characterized by enhanced sensory neurotransmission that underlies increased sensitivity to noxious stimuli and the perception of non-noxious stimuli as painful. Evidence from neurophysiological and pharmacological studies demonstrates that ATP produces pain by directly enhancing neuronal excitability via the activation of specific ligand-gated ion channels, the P2X3 and P2X2/3 receptors. In addition, ATP activates CNS glial cells (e.g. microglia) in response to persistent nociceptive stimulation. This latter effect involves several distinct receptor-mediated signaling pathways linked to the P2X4, P2X7 and P2Y(12) receptors. This review summarizes new data that places these purinergic signaling events in a mechanistic context that illustrates the ability of ATP to initiate and maintain states of heightened sensory neuron excitability associated with persistent pain. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19914722     DOI: 10.1016/j.tins.2009.10.003

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  62 in total

1.  P2X receptor antagonists for pain management: examination of binding and physicochemical properties.

Authors:  Rebecca J Gum; Brian Wakefield; Michael F Jarvis
Journal:  Purinergic Signal       Date:  2011-11-16       Impact factor: 3.765

Review 2.  Molecular and functional properties of P2X receptors--recent progress and persisting challenges.

Authors:  Karina Kaczmarek-Hájek; Eva Lörinczi; Ralf Hausmann; Annette Nicke
Journal:  Purinergic Signal       Date:  2012-05-01       Impact factor: 3.765

3.  Imaging P2X4 receptor lateral mobility in microglia: regulation by calcium and p38 MAPK.

Authors:  Estelle Toulme; Baljit S Khakh
Journal:  J Biol Chem       Date:  2012-03-05       Impact factor: 5.157

Review 4.  Role of astrocytes in pain.

Authors:  C-Y Chiang; B J Sessle; J O Dostrovsky
Journal:  Neurochem Res       Date:  2012-05-26       Impact factor: 3.996

5.  A putative extracellular salt bridge at the subunit interface contributes to the ion channel function of the ATP-gated P2X2 receptor.

Authors:  Ruotian Jiang; Adeline Martz; Sophie Gonin; Antoine Taly; Lia Prado de Carvalho; Thomas Grutter
Journal:  J Biol Chem       Date:  2010-03-22       Impact factor: 5.157

6.  P2X and NMDA receptor involvement in temporomandibular joint-evoked reflex activity in rat jaw muscles.

Authors:  T Watanabe; Y Tsuboi; B J Sessle; K Iwata; J W Hu
Journal:  Brain Res       Date:  2010-05-23       Impact factor: 3.252

7.  Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity.

Authors:  Robert E Sorge; Tuan Trang; Ruslan Dorfman; Shad B Smith; Simon Beggs; Jennifer Ritchie; Jean-Sebastien Austin; Dmitri V Zaykin; Heather Vander Meulen; Michael Costigan; Teri A Herbert; Merav Yarkoni-Abitbul; David Tichauer; Jessica Livneh; Edith Gershon; Ming Zheng; Keith Tan; Sally L John; Gary D Slade; Joanne Jordan; Clifford J Woolf; Gary Peltz; William Maixner; Luda Diatchenko; Ze'ev Seltzer; Michael W Salter; Jeffrey S Mogil
Journal:  Nat Med       Date:  2012-03-25       Impact factor: 53.440

8.  Spinal astrocytes produce and secrete dynorphin neuropeptides.

Authors:  Andrew Wahlert; Lydiane Funkelstein; Bethany Fitzsimmons; Tony Yaksh; Vivian Hook
Journal:  Neuropeptides       Date:  2013-01-03       Impact factor: 3.286

Review 9.  P2X receptors as drug targets.

Authors:  R Alan North; Michael F Jarvis
Journal:  Mol Pharmacol       Date:  2012-12-19       Impact factor: 4.436

10.  Amino acid sequence conservation of the algesic fragment of myelin basic protein is required for its interaction with CDK5 and function in pain.

Authors:  Andrei V Chernov; Albert G Remacle; Swathi K Hullugundi; Piotr Cieplak; Mila Angert; Jennifer Dolkas; Veronica I Shubayev; Alex Y Strongin
Journal:  FEBS J       Date:  2018-08-27       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.